SkyePharma announced a series of deals that both signaled the fulfillment of its promise of partnering two of its lead products and allowed the group to extend its drug delivery technology portfolio. The deals offer interesting insight into the company’s position and strategy in the evolving drug delivery market. This article focuses on the dual strategy of drug delivery service followed by SkyePharma for established pharma partners together with the development of proprietary formulations of products.